These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23902544)

  • 1. Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment.
    Shirota H; Klinman DM
    Immunotherapy; 2013 Aug; 5(8):787-9. PubMed ID: 23902544
    [No Abstract]   [Full Text] [Related]  

  • 2. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
    Jahrsdörfer B; Weiner GJ
    Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor microenvironment by immunotherapy: part 2.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
    Tam YK
    J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
    [No Abstract]   [Full Text] [Related]  

  • 7. A new mechanism for blocking myeloid-derived suppressor cells by CpG.
    Lechner MG; Epstein AL
    Clin Cancer Res; 2011 Apr; 17(7):1645-8. PubMed ID: 21288925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA; Lotze MT
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
    Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
    J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response.
    Wooldridge JE; Weiner GJ
    Curr Opin Oncol; 2003 Nov; 15(6):440-5. PubMed ID: 14624226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology meets immunology: the cancer-immunity cycle.
    Chen DS; Mellman I
    Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for cancer: focusing on developing treatments rather than drugs.
    Sznol M
    Curr Opin Investig Drugs; 2001 Jul; 2(7):957-8. PubMed ID: 11757798
    [No Abstract]   [Full Text] [Related]  

  • 16. CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy.
    Xu L; Wang C; Zhou Y; Ren T; Wen Z
    Immunol Lett; 2012 Feb; 142(1-2):55-63. PubMed ID: 22249078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cancer-related inflammation in the era of immunotherapy.
    Nakamura K; Smyth MJ
    Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy.
    Skeate JG; Otsmaa ME; Prins R; Fernandez DJ; Da Silva DM; Kast WM
    Front Immunol; 2020; 11():922. PubMed ID: 32499782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of whole and lysed sensitized lymphocytes on murine tumor growth and host survival.
    Greco RS; Schmidt DR; Storer EH
    Surg Forum; 1973; 24():109-11. PubMed ID: 4808028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.